Doyle Mittie bought AVTX
June 23, 2026 · Form 4 insider transaction
Doyle Mittie bought 1,450 shares of Avalo Therapeutics, Inc. at $8.04 per share, a transaction worth $11.7K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
1,450
Price
$8.04
Total value
$11.7K
InsiderDoyle Mittie
RoleOfficer, Director
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateJune 23, 2026
Filing dateJune 25, 2026
Shares owned after53,226
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.